scholarly journals Enteral Nutrition in Crohn’s Disease: An Underused Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
S. Kansal ◽  
J. Wagner ◽  
C. D. Kirkwood ◽  
A. G. Catto-Smith
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Practice ◽  
Enteral Nutrition ◽  
Mechanism Of Action ◽  
Bowel Disease ◽  
Safety Profile ◽  
Adult Patients ◽  
Exclusive Enteral Nutrition ◽  
Inflammatory Bowel ◽  
Putative Mechanism

This paper reviews the literature on the history, efficacy, and putative mechanism of action of enteral nutrition for inflammatory bowel disease in both paediatric and adult patients. It also analyses the reasoning behind the low popularity of exclusive enteral nutrition in clinical practice despite the benefits and safety profile.

The Role of Enteral Nutritional Therapy in Inflammatory Bowel Disease

2015 ◽  
Author(s):  
Lindsey Albenberg ◽  
Robert Baldassano
Keyword(s):  
Inflammatory Bowel Disease ◽  
Enteral Nutrition ◽  
Mechanism Of Action ◽  
Bowel Disease ◽  
Nutritional Therapy ◽  
Nutrition Therapy ◽  
Poor Growth ◽  
Inflammatory Bowel ◽  
Maintenance Of Remission ◽  
The Impact

Enteral nutrition therapy is a dietary treatment regimen for inflammatory bowel disease that has the benefit of avoiding suppression of the immune system. Its mechanism of action has not been well characterized, but may be related to the elimination of dietary antigens or modulation of the gut microbiota. This treatment has shown success for induction of remission, and may also have a role in maintenance of remission. In the pediatric population, enteral nutrition therapy has the dual benefit of targeting both the inflammatory processes and the poor growth of these patients. This review details the administration and mechanism of action of enteral nutritional therapy, the induction and maintenance of remission, the impact of enteral nutritional therapy on growth and nutrition, and side effects and quality of life. A table summarizes studies investigating enteral nutritional therapy for induction of remission. This review contains 1 table and 49 references.

scholarly journals Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

2010 ◽  
Vol 31 (5) ◽  
pp. 553-560 ◽  
Author(s):  
Y. ZABANA ◽  
E. DOMÈNECH ◽  
M. MAÑOSA ◽  
E. GARCIA-PLANELLA ◽  
I. BERNAL ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Practice ◽  
Bowel Disease ◽  
Safety Profile ◽  
Inflammatory Bowel

scholarly journals Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 414 ◽  
Author(s):  
Helena Rolandsdotter ◽  
Kerstin Jönsson-Videsäter ◽  
Ulrika L. Fagerberg ◽  
Yigael Finkel ◽  
Michael Eberhardson
Keyword(s):  
Inflammatory Bowel Disease ◽  
Enteral Nutrition ◽  
Bowel Disease ◽  
Induction Treatment ◽  
Clinical Effects ◽  
Diagnostic Colonoscopy ◽  
Exclusive Enteral Nutrition ◽  
Complete Clinical Remission ◽  
Before And After ◽  
Inflammatory Bowel

Exclusive Enteral Nutrition (EEN) is the first-line treatment in children with Crohn’s disease (CD) for induction of remission. However, the mode of action remains conjectural. The aim of this study was to investigate whether the effect of EEN is paralleled by changes in the mucosal cytokine profiles (MCP). Twelve children with new onset inflammatory bowel disease (IBD) received induction treatment with a polymeric EEN. We assessed clinical, endoscopic and histologic scoring before and after EEN. Twelve colonic cytokines were analyzed by Polymerase Chain Reaction (PCR) in six of the IBD patients at onset and after EEN as well as in six non-IBD control children at the diagnostic colonoscopy. Twelve children completed 6 weeks of EEN, except from one child who completed 4 weeks. At the control colonoscopy, 83% were in complete clinical remission. Changes were found in the MCPs of individual patients after EEN. In particular, children with IBD showed significantly higher values of Interleukin (IL)-12β (p = 0.008) and IL-23α (p = 0.02) compared to non-IBD controls at the diagnostic colonoscopy. Furthermore, an overall change in proinflammatory cytokines was noted in the IBD-group after treatment. Further studies are warranted to understand the role of EEN in MCP.

Sign in / Sign up

Export Citation Format

Share Document